MitoRx Therapeutics OXFORD, England, March 07, 2023 (Globe NEWSWIRE) — MitoRx Therapeutics (MitoRx), a biotechnology business acquiring revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the development of degenerative illnesses, announces Christine Charman as Main Enhancement Officer, David Richardson as Finance Director, and 4 appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd C Schwahn. Prof Chas Bountra OBE is now Chair of the Scientific Advisory Board. He commented on his appointment: “It’s an honour and a pleasure to appear alongside one another with major worldwide scientific and clinical experts to develop the MitoRx Scientific Advisory Board. Jointly we…